<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455180</url>
  </required_header>
  <id_info>
    <org_study_id>NL50578.029.14</org_study_id>
    <secondary_id>2014-003680-38</secondary_id>
    <nct_id>NCT02455180</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients</brief_title>
  <official_title>Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetic properties of two different
      dosage regimens of intravenous vitamin C in patients admitted to the Intensive Care Unit with
      life-threatening illness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:

      Critically ill patients with trauma or sepsis exhibit a high degree of vitamin C deficiency
      at ICU admission and vitamin C plasma concentrations decrease even more during the first
      three days of admission. Vitamin C is a natural anti-oxidant and crucial for endothelial and
      organ protection

      Objective:

      To determine the pharmacokinetics of two high dose regimens of intravenous vitamin C in
      critically ill patients, in particular the attained plasma concentration and the fraction
      retained in the body and excreted in urine.

      Study design:

      Prospective randomized controlled pharmacokinetic intervention study

      Study population:

      Adult critically ill patients admitted to the ICU of the VU University Medical Center,
      Amsterdam, with sepsis or SIRS after major surgery or trauma with a non-neurological
      sequential organ failure (SOFA) score &gt;6 and an expected length of ICU stay of &gt;96 hours.

      Intervention (if applicable):

      Patients will receive either 2 or 10 gram/day vitamin C intravenously twice daily for two
      days in bolus or continuous infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin C plasma concentration</measure>
    <time_frame>Baseline (before intervention), thereafter at 1, 2, 4, 8, 12, 24, 36, 48, 72, 96 hours after first intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin C excreted in urine</measure>
    <time_frame>0-12hours after first intervention; 36-48 hours after first intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxalate excretion in urine</measure>
    <time_frame>0-12hours after first intervention; 36-48 hours after first intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>F2-isoprostanes (oxidative damage biomarker)</measure>
    <time_frame>0, 24 and 72 hours after first intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CellROX (reactive oxygen species activity in leukocytes)</measure>
    <time_frame>0 and 24 hours after first intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor requirements (noradrenalin dose)</measure>
    <time_frame>0, 12, 24, 48, 72 and 96 hours after first intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal resistive index (ultrasonography)</measure>
    <time_frame>0, 4, 24, 72 hours after first intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine and creatinine clearance</measure>
    <time_frame>0, 24, 48, 72, 95 after first intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>0, 24, 48, 72, 95 after first intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Multiple Organ Failure</condition>
  <condition>Sepsis</condition>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>4x 1 gram bolus (q12H) dosage regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 gram of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 4 grams).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4x 5 grams bolus (q12H) dosage regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 grams of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 20 grams).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 gram continuous dosage regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 gram continuous dosage regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.</description>
    <arm_group_label>4x 1 gram bolus (q12H) dosage regimen</arm_group_label>
    <arm_group_label>4x 5 grams bolus (q12H) dosage regimen</arm_group_label>
    <arm_group_label>4 gram continuous dosage regimen</arm_group_label>
    <arm_group_label>20 gram continuous dosage regimen</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sepsis or Systemic Inflammatory Response Syndrome (SIRS) after major surgery or
             trauma;

          -  Non-neurological sequential organ failure assessment (SOFA) score &gt;6;

          -  Expected length of ICU stay &gt; 96 hours;

          -  Written proxy consent by legal representative.

        Exclusion Criteria:

          -  Admission after out of hospital cardiac arrest

          -  Prior use of supplemental vitamin C in the week before

          -  Major bleeding

          -  Pre-existent renal insufficiency defined as an eGFR of &lt; 30 ml/min/1.73 m2 (stadium
             4-5)

          -  Expected need for renal replacement therapy within 48 hours

          -  Known glucose 6-phosphate dehydrogenase deficiency

          -  History of urolithiasis or oxalate nephropathy

          -  Previous use of prolonged high dose vitamin C supplements

          -  Hemochromatosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H.M. Oudemans-van Straaten, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU University Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>H.M. Oudemans-van Straaten, MD, PhD</investigator_full_name>
    <investigator_title>Intensivist</investigator_title>
  </responsible_party>
  <keyword>Critical Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

